Results 41 to 50 of about 67,161 (291)

Complications of thrombolysis in an intensive care unit

open access: yesActa Medica Lituanica, 2012
Background. Thrombolysis is often the only way in treating people with life-threatening conditions, like acute myocardial infarction (AMI), pulmonary embolism (PE) and acute ischemic stroke (AIS).
Živilė Deimantavičienė   +6 more
doaj   +1 more source

Iodinated contrast media and cerebral hemorrhage after intravenous thrombolysis [PDF]

open access: yes, 2011
<p>Background and Purpose: Iodinated contrast is increasingly used in CT perfusion or angiographic examinations in acute stroke. Increased risk of intracranial hemorrhage (ICH) complicating microcatheter contrast injections has recently been ...
Evelyn Teasdale   +6 more
core   +1 more source

Fibrinogen Changes Before and After Intravenous Thrombolysis as Predictors of Cerebral Injury and Clinical Outcomes in Acute Ischemic Stroke: A Multicenter Prospective Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai   +28 more
wiley   +1 more source

Impact of Asymptomatic Intracranial Hemorrhage on Outcome After Endovascular Stroke Treatment

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Endovascular treatment (EVT) achieves high rates of recanalization in acute large‐vessel occlusion (LVO) stroke, but functional recovery remains heterogeneous. While symptomatic intracranial hemorrhage (sICH) has been well studied, the prognostic impact of asymptomatic intracranial hemorrhage (aICH) after EVT is less certain ...
Shihai Yang   +22 more
wiley   +1 more source

Treatment of the acute severe pulmonary embolism using endovascular methods [PDF]

open access: yes, 2018
Purpose: To present a single-centre experience with endovascular treatment of patients with severe symptoms secondary to acute pulmonary embolism (PE). Material and methods: Twenty-five patients were treated due to contraindications or deficient effects ...
Bursjoo, Carina   +2 more
core   +1 more source

Drug‐Free Thrombolysis Mediated by Physically Activated Micro/Nanoparticles

open access: yesAdvanced Functional Materials, EarlyView.
Overview of particle‐mediated thrombolytic effects (thermal, mechanical, and chemical) and their activating physical stimuli (light, ultrasound, and magnetic field) in drug‐free thrombolysis. ABSTRACT Thrombus‐associated disorders rank among the world's leading causes of death, with ischemic heart disease and stroke as the main contributors.
Pierre Sarfati   +2 more
wiley   +1 more source

Safety of alteplase intravenous thrombolysis and influencing factors of clinical outcome in elderly patients with acute ischemic stroke

open access: yesBMC Neurology
Objective To explore the safety of intravenous thrombolysis with alteplase (rt-PA) in the treatment of acute ischemic stroke (AIS) in the elderly (≥ 80 years old) and with analyze the influencing factors of its clinical outcome.
Yongyin Zhang   +6 more
doaj   +1 more source

Recurrent high-risk pulmonary thromboembolism treated with repeated thrombolytic therapy could be helpful for certain patients: a case report and review of the literature

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2023
Acute pulmonary thromboembolism (PTE) is considered the third most frequent acute cardiovascular syndrome behind myocardial infarction and stroke, with annual incidence rates ranging from 39 to 115 per 100,000 people and ranking high among the causes of ...
Leila Bigdelu   +2 more
doaj   +1 more source

Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up? [PDF]

open access: yes, 2020
Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as ...
Ataya, Ramsey, Brea, Isabel, Zitek, Tony
core  

Targeting the ARRDC3–DRP1 Axis via hUMSC‐Derived Exosomal CRYAB for Neuroprotection in Cerebral Ischemia/Reperfusion Injury

open access: yesAdvanced Healthcare Materials, EarlyView.
Intranasally administered hUMSC‐derived exosomes modulate the CRYAB–ARRDC3–Drp1 axis, alleviating mitochondrial dysfunction and ferroptosis, enhancing neuronal survival, reducing oxidative stress, and promoting functional recovery in ischemia‐reperfusion injury, offering a promising therapeutic strategy for ischemic stroke.
Rong ji   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy